ライフサイエンスコーパス: serum sample

1 d who provided at least one valid assessable serum sample.

2 s novel immunosensor was used to analyze the serum sample.

3 ination of complementary sequence in a human serum sample.

4 determination of epirubicin in a human blood serum sample.

5 ve detection of miRNAs from cell lysates and serum samples.

6 rference capability in the presence of human serum samples.

7 vant concentrations of lysozyme in undiluted serum samples.

8 x10(-21)M) both in control as well as spiked serum samples.

9 as a function of QA concentrations in human serum samples.

10 of the juvenile idiopathic arthritis in real serum samples.

11 in undiluted, immunoglobulin-deprived human serum samples.

12 e ebolavirus) variant Makona in spiked human serum samples.

13 pplied for the determination of Cys in blood serum samples.

14 re for the elimination of protein from human serum samples.

15 e similar response profile across polyclonal serum samples.

16 st with the negative results with 20 control serum samples.

17 the age range of the originator using human serum samples.

18 reover, it determined neopterin in synthetic serum samples.

19 vely analyzed with good reliability in human serum samples.

20 phenotypes has been found among 206 studied serum samples.

21 supernatants of stimulated primary cells and serum samples.

22 CR for miRNA analysis was performed using 70 serum samples.

23 samples such as drug, milk, honey and blood serum samples.

24 rgeted depletion of 5' tRNA halves in murine serum samples.

25 especially considering the complex nature of serum samples.

26 its complex with Ni(2+) by HRP-II present in serum samples.

27 aks recorded in the electropherograms of the serum samples.

28 various concentrations of standard NEFA and serum samples.

29 m model glycoproteins and pooled human blood serum samples.

30 etection limit (LOD) of 5.7 aM in real human serum samples.

31 ed successful in determining NSE in clinical serum samples.

32 glucose and cholesterol level of real human serum samples.

33 ated, together with successful validation in serum samples.

34 5846) of these proteins in individual plasma/serum samples.

35 ic antigen concentrations in patient-derived serum samples.

36 ferritin concentrations in spiked buffer and serum samples.

37 however challenging due to the complexity of serum samples.

38 detection of HER2 in complex matrix of human serum samples.

39 onses to DENV, as measured in healthy annual serum samples (79.7% vs 47.8%; P < .001).

40 In the serum samples, a total 3280 and 3225 ions of interest we

41 Moreover, real serum samples analysis were also carried out using immob

42 Besides, the real (juice and serum) sample analysis based on a standard addition meth

43 amount of IgG3-H435 relative to IgG-R435 in serum samples and (ii) the proportion of malaria-specifi

44 F-MS-based glycomic procedures to 20 control serum samples and 42 samples provided by patients diagno

45 applied to a convenience set of 96 unexposed serum samples and a blinded set of 80 samples treated wi

46 L5 were demonstrated using hyperimmune mouse serum samples and a curated panel of human serum.

47 ssed in seropositive patients with available serum samples and at least 2 years follow-up.

48 Measurements of sIL-2R and ACE in serum samples and data extraction from patient files wer

49 We serologically screened >2,000 1970s serum samples and developed a highly sensitive approach

50 of 25OHD, selecting 1666 cohort members with serum samples and ensuring representation in the subcoho

51 omatography in end-of-feeding-period fasting serum samples and expressed in both relative and absolut

52 for oxytocin determination in both synthetic serum samples and in aqueous solutions was similar and,

53 and 139 stage I-III CRC patients, as well as serum samples and matched primary and metastatic liver t

54 n of the immunosensor for CA125 detection in serum samples and measuring of ovarian-cancer cells was

55 ification of p53 protein in the human spiked serum samples and more importantly in the human normal a

56 mbryonic cell culture, beverages, urine, and serum samples and reused upto 200-times within a period

57 nsor was used to detect sialic acid in blood serum samples and the results were in good agreement wit

58 mic status were evaluated using direct blood serum sampling and ADOS.

59 ctivation products C3a, C4a and C5a in these serum samples, and found that serum levels of C3a and C5

60 reviously been reported in 22% to 100% of BP serum samples, and the pathogenic relevance of anti-BP18

61 O2 detection in the disinfected fetal bovine serum samples, and the recovery was obtained about 98%.

62 ide concentrations in maternal mid-pregnancy serum samples: association with autism spectrum disorder

63 From 2010 to 2011, we collected </= 3 serum samples at approximately 6-month intervals from 52

64 Detection of miRNA-21 in spiked serum samples at clinically relevant levels (low pM rang

65 protocol deviations, and provided evaluable serum samples at day 1 and the scheduled timepoints thro

66 Mother-neonate paired serum samples at delivery were tested for IgG to antigen

67 immune evasion in nonhuman primate and human serum samples at dilution factors as high as 1:5, curren

68 assessed in concurrently obtained urine and serum samples at the 24-month or last on-treatment visit

69 a definitive diagnosis of MG with available serum samples at the time of diagnosis.

70 equency questionnaire and provided a fasting serum sample before study randomization (1985-1988).

71 We collected serum samples before and after immunisation, and cord bl

72 When tested in a human serum sample between 25 and 43 degrees C, the sensor had

73 lpha, in gingival crevicular fluid (GCF) and serum samples between women with preterm birth (PTB) and

74 Finally, ABBA serum samples but not control samples showed reactivity

75 luding IgG and IgM, individually in a single serum sample by using commercially available kits.

76 able for concentration ranges encountered in serum samples by adjusting the Fe3O4@GO Concentration.

77 This study included women with a serum sample collected early (<140 days gestation) in th

78 nzyme-linked immunosorbent assays in GCF and serum samples collected 24 to 48 hours after labor from

79 Archived serum samples collected as part of an ongoing pediatric

80 erved peripheral blood mononuclear cells and serum samples collected at baseline, at 1- and 2-year tr

81 d next-generation sequencing on microRNAs in serum samples collected before injury and then at 1, 3,

82 s were also observed in approximately 56% of serum samples collected during 1970-1999 (20% IgG, 19% I

83 ers of meat consumption was undertaken using serum samples collected from combining high resolution m

84 The system was validated with undiluted serum samples collected from trauma patients at the inte

85 Serum samples collected within 1 hour after exposure wer

86 region of birth in Finland, date of maternal serum sample collection, date of mother's birth, and dat

87 hile miR-26b was markedly decreased in AAAD+ serum samples compared with AAAD- individuals.

88 the IgG proteolytic activity and that piglet serum samples contain specific antibodies against IgdE s

89 Results from field serum samples demonstrated that all of the synthetic ant

90 st time, the present study demonstrated that serum sample denaturation decreases the test specificity

91 using purified protein solution and clinical serum samples depict high sensitivity, specificity and w

92 We used serum samples derived from a cohort of patients with GBS

93 Using serum sample dilution, and nondenaturation, the lowest l

94 e-stranded RNA in bronchoalveolar lavage and serum samples following lung contusion was measured.

95 bioprobe can be employed for QA detection in serum sample for the early detection of many diseases.

96 PANSS, ACE-III, GAF) at baseline, and tested serum samples for antibodies against NMDAR, LGI1, CASPR2

97 h in which a redox mediator is used to probe serum samples for chemical information relevant to oxida

98 system can be successfully applied to human serum samples for determining LDL concentrations.

99 ctivity of alpha amylase enzyme in urine and serum samples for early diagnosis of Pancreatitis diseas

100 ersion between baseline and post-vaccination serum samples for measles, rubella, and yellow fever; an

101 ok an affinity proteomic approach to profile serum samples for proteins that could serve as indicator

102 detection of anti-PCV3 capsid antibodies in serum samples found that 46 (55%) of 83 samples tested w

103 innish Maternity Cohort and had an available serum sample from the pregnancy with the affected child.

104 hy-mass spectrometry, we measured 25(OH)D in serum samples from 1,611 women who later developed breas

105 Serum samples from 103 cases of coccidioidomycosis and 3

106 dy to determine circulating mtDNA content in serum samples from 116 HBV-related HCC cases and 232 fre

107 Paired serum samples from 121 children with acute wheezing were

108 pseudomallei The ELISAs were evaluated using serum samples from 141 culture-confirmed melioidosis pat

109 d Methods Ten genes were tested in duplicate serum samples from 141 women at baseline, at week 4, and

110 report eight coding-complete genomes from US serum samples from 1978-1979-eight of the nine oldest HI

111 Serum samples from 198 APAP-ALF patients (nested case-co

112 Serum samples from 204 adult ALF patients collected from

113 B19V DNA-positive serum samples from 222 immunocompetent individuals were

114 Serum samples from 235 individuals with syphilis were te

115 fferent laboratories in Europe on plasma and serum samples from 28 individuals.

116 Acute-phase serum samples from 346 patients with a suspected arbovir

117 Serum samples from 475 participants with 6-month data we

118 Here, we screened serum samples from 50 patients positive for PLA2R1 for i

119 Serum samples from 505 patients with CNS inflammatory di

120 PTX3 expression was assessed in tissue and serum samples from 54 patients with alcoholic hepatitis.

121 levels were quantitated by ELISA in BALF and serum samples from 60 LTRs.

122 performed microRNA (miRNA) profiling in 318 serum samples from 69 liver transplant recipients enroll

123 kage is illustrated with a data set of blood serum samples from 7 diet induced obese (DIO) and 7 nono

124 the Finnish Maternity Cohort, a cohort with serum samples from 98% of pregnancies registered in Finl

125 Blinded serum samples from a cohort of 58 immunodeficiency patie

126 We analyzed serum samples from a subset of 47 children who had recei

127 achieve our objective, we assessed miRNAs in serum samples from AD patients and Mild cognitive impair

128 We examined serum samples from adults ages 48-64 who received multip

129 We quantified ADCC-Abs in serum samples from adults who received a dose of inactiv

130 3.33, p < 0.001) and individual (p = 0.009) serum samples from ASD versus TD children.

131 mplement levels and complement regulation in serum samples from carriers and noncarriers.

132 y available anti-BHV-1 antiserum and in real serum samples from cattle with results being in excellen

133 We collected discarded serum samples from children and adolescents (aged </=21

134 y acquired DENV antibodies was determined in serum samples from children enrolled in the cohort.

135 y human IgE binding by inhibition ELISA with serum samples from children with clinical allergic sympt

136 In the serum samples from children with otitis media infected w

137 In addition, we demonstrate that serum samples from dengue-immune pregnant women enhanced

138 o discriminate the JIA positive and negative serum samples from different individuals using different

139 iomarkers we performed proteome profiling of serum samples from DMD and IBD patients with and without

140 We screened serum samples from DR patients and controls using primar

141 We analyzed serum samples from four AD patients who had received ora

142 Serum samples from healthy control subjects and patients

143 JIA positive sample than for a pool of human serum samples from healthy individuals.

144 nward-flow immunoassay, we tested 200 stored serum samples from high-risk patients enrolled in a long

145 nti-HIV Ab effector activities in polyclonal serum samples from HIV-infected donors, VAX004 vaccine r

146 ited paired euthyroid and severe hypothyroid serum samples from human subjects.

147 We evaluated our results on human serum samples from lymphoma patients and healthy control

148 dy of de-identified residual diagnostic test serum samples from males aged 15-39 years from laborator

149 In an analysis of serum samples from more than 500 patients with IBD, we o

150 ns naturally infected with DENV2 or DENV3 in serum samples from Nicaragua collected at acute, convale

151 Twenty serum samples from of patients after AHSCT without cGVHD

152 Using a large cohort of serum samples from osteosarcoma patients (n = 233), we v

153 Twenty serum samples from patients after AHSCT without cGVHD we

154 We also measured levels of soluble B7 serum samples from patients and controls, and mice with

155 ytokine enzyme-linked immunosorbent assay of serum samples from patients with acute and chronic hepat

156 serum samples from patients with acute Hepatitis A (12/

157 of IFNgamma and TNF-alpha were increased in serum samples from patients with acute vs chronic hepati

158 Serum samples from patients with autoimmune diseases wer

159 We profiled ACAAs in a diverse cohort of serum samples from patients with immunodeficiency and as

160 s built and applied to an independent set of serum samples from patients with OA (n = 188), control i

161 spension bead arrays were applied to analyze serum samples from patients with OA (n = 273), control s

162 ectively measure specific antibody levels in serum samples from patients with varied infectious or au

163 zing antibody responses, convalescence-phase serum samples from people previously exposed to primary

164 We found that rhPAPPA and PAPPA in the serum samples from pregnant women or conditioned medium

165 A pool of serum samples from prostate cancer patients with known t

166 using the 4,000-plex SOMAscan assay on 1,470 serum samples from seven countries where TB is endemic.

167 ical diagnosis was demonstrated by analysing serum samples from seven healthy volunteers.

168 tested our newly developed method on serial serum samples from severe TBI (sTBI) patients (n = 72) a

169 We used the microarrays to analyze serum samples from SLE patients and found individuals wi

170 dy, we investigate 20,152 general-population serum samples from southern Vietnam collected between 20

171 To this end, longitudinal serum samples from survivors of Sudan ebolavirus (SUDV)

172 Serum samples from the patient reacted with the brush bo

173 sensitivities of 77%, 45%, and 9% in bovine serum samples from the United Kingdom (n = 126), the Uni

174 olites characteristically enriched in paired serum samples from these patients.

175 An additional 120 serum samples from tuberculosis, scrub typhus, or leptos

176 Assays of 6 prostate cancer patient serum samples gave good correlation with conventional si

177 We also demonstrate in spiked serum sample high selectivity towards target HER2 protei

178 Serum samples identified as positive for total anti-HBc,

179 ethod for non-HDL-P quantification in native serum samples implies daily calculation of the electrosp

180 er transforms infrared spectroscopy of dried serum samples in an effort to assess biochemical changes

181 nt titer distributions and the proportion of serum samples in each, from which estimates of PEF were

182 sensor was able to quantify cocaine in blood serum samples in the range of concentrations between 1nM

183 ificity and excellent recovery for the human serum samples, indicating its promising potential in bio

184 reagent for quantification of ACY-1 in blood serum samples is also explored.

185 At the conclusion of the feeding protocol, serums samples, livers or isolated neutrophils were util

186 A total of 29 miRNAs were quantified in serum samples (n = 300) using a nested case-control stud

187 Pretreatment and on-treatment serum samples (n = 740) from patients with HCV genotype

188 In this study, we used serum samples (n = 792) from pigs of precisely known inf

189 rmed nasopharyngeal or nasal swabbing and/or serum sampling (n = 148) in Lancaster, UK, over the wint

190 n = 142), and (2) longitudinal with repeated serum sampling (n = 246, median follow-up = 3.1 years, i

191 We measured TMAO in stored serum samples obtained 3-6 months after randomization fr

192 nsion cohorts at the same study site who had serum samples obtained at multiple early timepoints.

193 cid analysis of aqueous humour, vitreous and serum samples obtained during surgery from a 24 year old

194 Serum samples obtained every 6 months were evaluated for

195 Paired human hair, fingernail, toenail, and serum samples obtained from 50 adult participants recrui

196 d pellets (WBP), 583 plasma samples, and 419 serum samples obtained from hematology patients accordin

197 performed with analysis of the PSA levels in serum samples obtained from patients with prostate cance

198 e and sensitive for [3-Nty](-2) at pH 7.3 in serum sample of liver cirrhosis with MHE diseases.

199 sor for the assessment of 3-Nty in different serum samples of (MHE) in patients with liver cirrhosis.

200 We screened serum samples of 1276 patients with MN from three differ

201 We then analyzed exosomes isolated from serum samples of 156 patients using a qRT-PCR array for

202 Serum samples of 2 of 6 patients with positive reactivit

203 Serum samples of 501 nonselected pupils from Salzburg, A

204 Serum samples of 681 adults enrolled in the U.S. Acute L

205 BDNF is increased in the serum samples of adults with AD.

206 Serum samples of cases and controls and cerebrospinal fl

207 Serum samples of children with APAP overdose had signifi

208 nd/or 91 mutant HCV quasispecies in baseline serum samples of chronic HCV patients from the HALT-C tr

209 yed for the estimation of uric acid in blood serum samples of healthy individuals.

210 -activating capabilities of antiviral IgG in serum samples of long recovered survivors.

211 identified a serum miRNA signature in human serum samples of mild to severe TBI, which can be used f

212 Human serum samples of MMTBI, severe TBI (STBI), orthopedic in

213 Stored serum samples of National Health and Nutrition Examinati

214 vity range (3-321U/L) in different urine and serum samples of pancreatitis patients.

215 Serum samples of patients with CSU together with those o

216 in the retinas of diabetic mice (3-fold) and serum samples of patients with diabetic macular edema (1

217 c profiling of N-glycans released from blood serum samples of patients with different esophageal dise

218 sine (PLL) film was developed and applied to serum samples of prostate cancer positive for Gleason sc

219 d samples of the "usually" consumed milk and serum samples of the children were collected at age 4 ye

220 ated by the weekly testing of sow and piglet serum samples on a SVA VP1 recombinant protein (rVP1) in

221 dy levels in real time and in un-manipulated serum samples on-site where needed.

222 s of 150-250 IU/mL; using nondenaturation of serum samples, our HCV-Ags EIA reliably differentiated V

223 ive sensor prototypes were tested in a human serum sample over one week and the maximum deviation of

224 from the ironPhone for the buffer and spiked serum samples provided a calibration curve with R(2) val

225 In human serum samples, PYY concentrations were higher in samples

226 rst time in human samples in 5 to 10% of the serum samples, ranging from 50 to 80 pg/mL.

227 A metallomic profile of 110 CSF and 530 serum samples showed significant variations in 10 elemen

228 Validation with human serum samples shows an excellent agreement when compared

229 ion of circulating microRNAs (miRNA, miR) in serum samples specific to patients with very high-risk (

230 s of aqueous and organic extracts from human serum samples, spectral features were assigned to a tota

231 Community Respiratory Health Survey provided serum samples, spirometry, and questionnaire data about

232 he SALDI-MS results obtained on the desalted serum sample spots show both good reproducibility and co

233 s were measured in maternal second trimester serum samples stored from routine screening.

234 an 0.7 pmol/g lw) but was below detection in serum samples, suggesting low or no bioavailability for

235 Thirty-three percent of all 108 serum samples tested yielded viral RNA.

236 All mouse and human serum samples that were able to neutralize rMuVJL5 infec

237 pecificity, 84%) to reduce the proportion of serum samples that were required by the more cumbersome

238 undiluted human serum as well as artificial serum sample, the slope of the linear calibration at the

239 d FTO electrode for determining ACh level in serum samples, the applicability of biosensor has increa

240 posed biosensor was introduced to real human serum samples to determine HSP70 sensitively and accurat

241 ions of DENV-reactive antibodies from immune serum samples to estimate the contribution of serotype-c

242 the current study we analyzed depleted human serum samples to evaluate experimental factors that may

243 Subsequently, serum samples, tonsil swabs, and feces were collected fr

244 power of COLMARm is demonstrated for a human serum sample uncovering the existence of 14 metabolites

245 tis B surface antigen (anti-HBs) in clinical serum samples using surface plasmon resonance (SPR).

246 ity, a diagnosis that was validated when her serum sample was found to contain antibodies to S-arrest

247 Each serum sample was subjected to Toxocara excretory - secre

248 nce of anti-Pneumocystis antibodies in human serum samples was detected by ELISA and Western blotting

249 neous detection of CA125 and CA15-3 in human serum samples was evaluated and the obtained results wer

250 sensor for analysis of lactate in artificial serum samples was evaluated with good satisfactory resul

251 or in common interferents and clinical human serum samples was investigated, showing comparable to EL

252 rations at low levels (few pgmL(-1)) in real serum samples was successfully evaluated.

253 this assay to recipient post-HCT plasma and serum samples, we demonstrated reactivation of HHV-6B in

254 By quantifying 13 HCMV miRNAs in serum samples, we found that the levels of HCMV-miR-US4-

255 Serum samples were analysed for total IgE levels and ant

256 (BAL) and lung tissue, and total free IgE in serum samples were analyzed 24, 48, and 96 hours after t

257 Clinical serum samples were analyzed by using a novel biointerfac

258 -14 weeks) and third-trimester (30-34 weeks) serum samples were analyzed using targeted metabolomic (

259 Both maternal and cord serum samples were assayed for levels of IgG1 and IgG3 s

260 In group 1, 91 serum samples were available for analysis 1 month after

261 imaging and other methods; tumor, liver, and serum samples were collected and assessed by histochemic

262 Serum samples were collected at 7, 14 and 21 day post in

263 Seventy percent of serum samples were collected during the first trimester

264 Serum samples were collected from 35 individuals with id

265 Paired stool and serum samples were collected from a subset of patients w

266 Serum samples were collected from patients and 291 match

267 Serum samples were collected in 2005-2006 and analyzed f

268 Serum samples were collected over a median time period o

269 Saliva and serum samples were collected, and HDM-specific, IgE, IgG

270 d 2 OCPs measured in banked second-trimester serum samples were compared between the diagnostic group

271 LISA method in AFP and CA125 measurements of serum samples were less than 12%.

272 Paired milk and serum samples were measured for PBDE concentrations in 3

273 Paired milk and serum samples were measured for PBDE concentrations in 3

274 IL-8 spiked serum samples were measured with a high reproducibility

275 Serum samples were obtained at 1.5-2 months from 106 stu

276 Follow-up serum samples were obtained at 7 months from 42 vaccinat

277 Serum samples were obtained at enrollment to quantify th

278 Serum samples were obtained before and after IVIG treatm

279 Infant serum samples were obtained before the first and second

280 Serum samples were obtained from a crossover clinical st

281 Serum samples were obtained from carriers of identified

282 Clinical measurements were recorded; GCF and serum samples were obtained from each participant before

283 Frozen serum samples were subjected to sclerostin quantitative

284 Prior to medical consultation, serum samples were taken and the Beck Depression Invento

285 Serum samples were taken from pediatric heart transplant

286 Maternal serum samples were tested by plaque reduction neutralisa

287 Serum samples were tested for autoimmune encephalitis Ab

288 A total of 184 serum samples were tested for both GPC3 by ELISA, and AF

289 Serum samples were tested with microneutralization and h

290 diagnostic sensitivity by only 2.2% (1 of 46 serum samples) when combined with the IgG anti-BP180 enz

291 ering light from any molecule present in the serum sample which can be also immobilised on the nanofi

292 rry out quantitative troponin I detection in serum samples with < 2microl sample volume in 5min.

293 ombining small RNA sequencing from 179 human serum samples with a neural network analysis produced a

294 bodies to multiple viral antigens in patient serum samples with detection limits for human IgG in the

295 The method enabled analysis of patient serum samples with elevated ProGRP levels.

296 Serum samples with higher RPC-reactive IgG levels induce

297 or the detection of tetracycline in milk and serum samples with LODs of 740 and 710 pM, respectively.

298 OME in pharmaceutical formulation and human serum samples with mean recoveries of 100.97% and 98.58%

299 and sixty-three metabolites were measured in serum samples with the AbsoluteIDQ kit p150 (Biocrates)

300 ucose assays in standard solutions and human serum samples worked reproducibly with close to 100% rec